The Efficacy and Safety of Intravitreal Dexamethasone Implant as Anti-inflammatory Monotherapy in the Management of Tuberculosis-associated Intermediate Uveitis

References

• Parchand S, Tandan M, Gupta V, et al. Intermediate uveitis in Indian population. J Ophthalmic Inflamm Infect. 2011;1(2):65–70. doi:10.1007/s12348-011-0020-3.
   PubMedGoogle Scholar
• Bansal R, Gupta A, Gupta V, et al. Role of anti-tubercular therapy in uveitis with latent/manifest tuberculosis. Am J Ophthalmol. 2008;146(5):772–779.doi:10.1016/j.ajo.2008.06.011.
   PubMed Web of Science ®Google Scholar
• Agrawal R, Gupta B, Gonzalez-Lopez JJ, et al. The role of anti-tubercular therapy in patients with presumed ocular tuberculosis. Ocul Immunol Inflamm. 2015;23(1):40–46.doi:10.3109/09273948.2014.986584.
   PubMed Web of Science ®Google Scholar
• Agrawal R, Testi I, Bodaghi B, et al. Collaborative ocular tuberculosis study consensus group. Collaborative ocular tuberculosis study consensus guidelines on the management of tubercular uveitis-report 2: guidelines for Initiating antitubercular therapy in anterior uveitis, intermediate uveitis, panuveitis, and retinal vasculitis. Ophthalmology. 2021 Feb;128(2):277–287. doi:10.1016/j.ophtha.2020.06.052.
   PubMed Web of Science ®Google Scholar
• Cheung CM, Chee SP. Jarisch–Herxheimer reaction: paradoxical worsening of tuberculosis chorioretinitis following initiation of antituberculous therapy. Eye. 2009;23(6):1472–1473. doi:10.1038/eye.2008.204.
   PubMed Web of Science ®Google Scholar
• Gupta V, Bansal R, Gupta A. Continuous progression of tubercular serpiginous-like choroiditis after initiating antituberculosis treatment. Am J Ophthalmol. 2011;152(5):857–63.e2. doi:10.1016/j.ajo.2011.05.004.
   PubMed Web of Science ®Google Scholar
• Basu S, Nayak S, Padhi TR, Das T. Progressive ocular inflammation following anti-tubercular therapy for presumed ocular tuberculosis in a high-endemic setting. Eye. 2013;27(5):657–662. doi:10.1038/eye.2013.5.
   PubMed Web of Science ®Google Scholar
• Tagirasa R, Parmar S, Barik MR, Devadas S, Autoreactive BS. T cells in immunopathogenesis of TB associated uveitis. Invest Ophthalmol Vis Sci. 2017;58:5682–5691. doi:10.1167/iovs.17-22462.
   PubMed Web of Science ®Google Scholar
• Hosoya K, Tachikawa M. Inner blood-retinal barrier transporters: role of retinal drug delivery. Pharm Res. 2009;26(9):2055–2065. doi:10.1007/s11095-009-9930-2.
   PubMed Web of Science ®Google Scholar
• Lowder C, Belfort R Jr, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. JAMA Ophthalmol. 2011;129(5):545–553.
   Google Scholar
• McAllister WA, Thompson PJ, Al-Habet SM, Rogers HJ. Rifampicin reduces effectiveness and bioavailability of prednisolone. Br Med J (Clin Res Ed). 1983;286(6369):923–925. doi:10.1136/bmj.286.6369.923.
   PubMedGoogle Scholar
• Goldfien A. Adrenocorticosteroids and adrenocortical antagonists. In: Katzung BG, ed. Basic and Clinical Pharmacology. 6th ed. London: Prentice Hall International; 1995:592–607.
   Google Scholar
• Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011 Jan 5;52(1):80–86. doi:10.1167/iovs.10-5285. PMID: 20702826.
   PubMed Web of Science ®Google Scholar
• Fonollosa A, Llorenç V, Artaraz J, et al. Safety and efficacy of intravitreal dexamethasone implants in the management of macular edema secondary to infectious uveitis. Retina. 2016 Sep; 36(9): 1778–1785. PMID: 27183031. doi:10.1097/IAE.0000000000001001.
   PubMed Web of Science ®Google Scholar
• Saincher SS, Gottlieb C. Ozurdex (dexamethasone intravitreal implant) for the treatment of intermediate, posterior, and panuveitis: a systematic review of the current evidence. J Ophthalmic Inflamm Infect. 2020;10:1. doi:10.1186/s12348-019-0189-4.
   PubMed Web of Science ®Google Scholar
• Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–516. doi:10.1016/j.ajo.2005.03.057.
   PubMed Web of Science ®Google Scholar
• Nachiappan AC, Rahbar K, Shi X, et al. Pulmonary tuberculosis: role of radiology in diagnosis and management. Radiographics. Jan-Feb 2017;37(1):52–72. doi:10.1148/rg.2017160032.
   PubMed Web of Science ®Google Scholar
• Bhalla AS, Das A, Naranje P, Goyal A, Guleria R, Khilnani GC. Dilemma of diagnosing thoracic sarcoidosis in tuberculosis endemic regions: an imaging-based approach. Part 1. Indian J Radiol Imaging. 2017 Oct-Dec;27(4):369–379. doi:10.4103/ijri.IJRI_200_17.
   PubMedGoogle Scholar
• Bhalla AS, Das A, Naranje P, Goyal A, Guleria R, Khilnani GC. Dilemma of diagnosing thoracic sarcoidosis in tuberculosis-endemic regions: an imaging-based approach. Part 2. Indian J Radiol Imaging. 2017 Oct-Dec;27(4):380–388. doi:10.4103/ijri.IJRI_201_17.
   PubMedGoogle Scholar
• Cohn DL. The effect of BCG vaccination on tuberculin skin testing: does it matter? Am J Respir Crit Care Med. 2001;164(6):915–916. doi:10.1164/ajrccm.164.6.2107090c.
   PubMed Web of Science ®Google Scholar
• Fonollosa A, Valsero S, Artaraz J, Ruiz-Arruza I. Dexamethasone intravitreal implants in the management of tubercular multifocal serpiginoid choroiditis. J Ophthalmic Inflamm Infect. 2016;6(1):31. doi:10.1186/s12348-016-0101-4.
   PubMed Web of Science ®Google Scholar
• Hasanreisoglu M, Ikiz GG, Aktas Z, Ozdek S. Intravitreal dexamethasone implant as an option for anti-inflammatory therapy of tuberculosis uveitis. Int Ophthalmol. 2019;39(2):485–490. doi:10.1007/s10792-018-0831-4.
   PubMed Web of Science ®Google Scholar
• Agarwal A, Handa S, Aggarwal K, et al. The role of dexamethasone implant in the management of tubercular uveitis. Ocul Immunol Inflamm. 2018;26(6):884–892. doi:10.1080/09273948.2017.1400074.
   PubMed Web of Science ®Google Scholar
• Jain L, Panda KG, Basu S. Clinical outcomes of adjunctive sustained-release intravitreal dexamethasone implants in tuberculosis-associated multifocal serpigenoid choroiditis. Ocul Immunol Inflamm. 2018;26(6):877–883. doi:10.1080/09273948.2017.1383446.
   PubMed Web of Science ®Google Scholar
• Ryder SJ, Iannetta D, Bhaleeya SD, et al. Efficacy and tolerability of bilateral sustained-release dexamethasone intravitreal implants for the treatment of noninfectious posterior uveitis and macular edema secondary to retinal vein occlusion. Clin Ophthalmol. 2015;9:1109. doi:10.2147/OPTH.S84207.
   PubMed Web of Science ®Google Scholar
• Rajesh B, Zarranz-Ventura J, Fung, et al. Safety of 6000 intravitreal dexamethasone implants. Br J Ophthalmol. 2020;104(1):39–46. doi:10.1136/bjophthalmol-2019-313991.
   PubMed Web of Science ®Google Scholar
• Malclès A, Dot C, Voirin N, et al. Safety of intravitreal dexamethasone implant (Ozurdex): the SAFODEX study. Incidence and risk factors of ocular hypertension. Retina. 2017;37(7):1352–1359. doi:10.1097/IAE.0000000000001369.
   PubMed Web of Science ®Google Scholar